Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhui Xue

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The Prostate|April 11, 2025
Understanding Enzalutamide-Resistance Based on a Functional Single-Cell ApproachChanghui Xue, Hyun-Kyung Ko, Kasen Shi, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Understanding the development of enzalutamide resistance based on a functional single-cell approachChanghui Xue, Hyun-Kyung Ko, Kasen Shi, et al.
Scientific Reports|October 4, 2016
Systemic Inhibition of CREB is Well-tolerated in vivoBingbing X Li, Ryan Gardner, Changhui Xue, et al.
Frontiers in Cell and Developmental Biology|November 25, 2021
HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-InhibitionHao Geng, Hyun-Kyung Ko, Janet Pittsenbarger, et al.
BMC Musculoskeletal Disorders|August 16, 2025
Risk factors for subsequent vertebral fractures after percutaneous vertebral augmentation in Asian populations: a systematic review and meta-analysisWeijie Zheng, Jiexin Huang, Liang Jin, et al.
Oncotarget|December 2, 2015
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinomaHui-Wen Lue, Brook Cole, Soumya A M Rao, et al.
Cell Reports. Medicine|June 7, 2021
Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinomaHui-Wen Lue, Daniel S Derrick, Soumya Rao, et al.
Nature Communications|January 10, 2019
Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Nature Communications|November 28, 2018
Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Prostate|April 11, 2025
Understanding Enzalutamide-Resistance Based on a Functional Single-Cell ApproachChanghui Xue, Hyun-Kyung Ko, Kasen Shi, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Understanding the development of enzalutamide resistance based on a functional single-cell approachChanghui Xue, Hyun-Kyung Ko, Kasen Shi, et al.
Scientific Reports|October 4, 2016
Systemic Inhibition of CREB is Well-tolerated in vivoBingbing X Li, Ryan Gardner, Changhui Xue, et al.
Frontiers in Cell and Developmental Biology|November 25, 2021
HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-InhibitionHao Geng, Hyun-Kyung Ko, Janet Pittsenbarger, et al.
BMC Musculoskeletal Disorders|August 16, 2025
Risk factors for subsequent vertebral fractures after percutaneous vertebral augmentation in Asian populations: a systematic review and meta-analysisWeijie Zheng, Jiexin Huang, Liang Jin, et al.
Oncotarget|December 2, 2015
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinomaHui-Wen Lue, Brook Cole, Soumya A M Rao, et al.
Cell Reports. Medicine|June 7, 2021
Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinomaHui-Wen Lue, Daniel S Derrick, Soumya Rao, et al.
Nature Communications|January 10, 2019
Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Nature Communications|November 28, 2018
Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Pageof 3